pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN
Lxo Ireland Designated
Lxo Ireland Designated Activity Company
Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP
CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- CARLSBAD, CA, IE
- Programs
- 68
- Drugs
- 61
- Patents
- 201
REX-001
Phase 3 · small molecule · Peripheral Arterial Disease (PAD)
REX-001 for Peripheral Arterial Disease (PAD) is a Phase 3 program (small_molecule) at Lxo Ireland Designated Activity Company with 2 ClinicalTrials.gov record(s).
Internal code REX-001-004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lxo Ireland Designated Activity Company
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Peripheral Arterial Disease (PAD)
- Status
- terminated
- Trials
- 2